Johnson & Johnson (JNJ)
Health Care11 articles
Market Mood
IHE vs IXJ: 39.7% vs 10% 1-Year Returns in ETFs Comparison
The iShares U.S. Pharmaceuticals ETF (IHE) has posted a 1-year return of 39.70% as of May 20, 2026, while the iShares Global Healthcare ETF (IXJ) reported a return of 10.00%. Both funds have similar expense ratios, with IHE at 0.38% and IXJ at 0.40%. IHE's assets under management (AUM) stand at $883.6 million, compared to IXJ's $3.6 billion. Additionally, IHE has a higher dividend yield of 1.70% versus IXJ's 1.50%, indicating potential advantages for investors favoring domestic pharmaceutical exposure.
Read More
Dividend Portfolio Yield Impacts After Taxes for California Residents
A retiree in California with a $1 million dividend portfolio earning a 5% yield generates $50,000 in gross income. After federal and state taxes, the net income drops to approximately $38,300, compared to $42,500 in states with no income tax, highlighting a $4,200 annual after-tax gap. California taxes dividends as ordinary income, with state rates ranging from 9.3% to 13.3%. Key dividend stocks mentioned include Johnson & Johnson (JNJ) at a 2.2% yield and Procter & Gamble (PG) at 3.0%.
Read More
Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion
Johnson & Johnson (JNJ) reported Q1 2026 revenue of $24.06 billion, representing a 9.9% year-over-year increase, driven by TREMFYA's growth of 68.3% and DARZALEX's increase of 22.5% to $3.96 billion. The company raised its full-year guidance to a midpoint of $100.8 billion. AbbVie (ABBV) also exceeded expectations with Q1 revenue of $15 billion and a year-over-year increase of 12.4%. AbbVie's Skyrizi reached $4.48 billion with a 30.9% increase, offsetting Humira's 38.6% decline.
Read More
Berkshire's Dividend Stock Picks: JNJ, MCD, PG for Market Downturn
Warren Buffett's Berkshire Hathaway held nearly $375 billion in cash at the end of 2025, indicating potential readiness for market downturn investments. The article identifies Johnson & Johnson (JNJ), McDonald's (MCD), and Procter & Gamble (PG) as favorable dividend stock picks in such a scenario. JNJ currently trades at about 19 times forward earnings but could become more attractive with a 20% to 25% pullback, yielding a dividend of 2.5% to nearly 3%. The dividends and consistent earnings growth of these companies highlight their stability during economic uncertainty.
Read More
Johnson & Johnson (JNJ) Launches Shockwave C2 Catheter for Coronary Procedures
Johnson & Johnson (JNJ) announced the launch of the Shockwave C2 Aero coronary catheter designed to treat coronary artery disease. This device aims to improve patient outcomes by facilitating easier and more effective treatments. The introduction of such innovative products could enhance JNJ's market position in the cardiovascular segment. As the demand for advanced medical technologies continues to grow, this launch may positively influence JNJ's market performance.
Read More
Dividend Portfolio Generates $17,500 Income from $500,000 Investment
A $500,000 portfolio yielding 3.5% can generate $17,500 annually, or about $1,460 per month, surpassing the federal minimum wage of $15,080 before taxes. For a 6% yield, the income increases to $30,000 annually, equating to $2,500 monthly, which also exceeds many state minimum wages. Notable investment options include Schwab U.S. Dividend Equity ETF (SCHD) and Realty Income (O), with established dividend increases. This analysis highlights the importance of yield versus compounding in portfolio growth over time.
Read More
Bayer (BAYRY) Loses Bid Against Johnson & Johnson Prostate Drug Claims
A US judge rejected Bayer's (BAYRY) motion to block claims regarding Johnson & Johnson's (JNJ) prostate cancer drug. This ruling may affect Bayer's legal exposure related to similar product liabilities. The case underscores ongoing competitive pressures in the pharmaceutical sector, particularly regarding patent and claim disputes. Bayer's strategy and resource allocation may be impacted by this decision as they navigate the legal landscape.
Read More
Johnson & Johnson (JNJ) Stock Target Increased After Earnings Report
Stifel has raised its price target for Johnson & Johnson (JNJ) following the company's latest earnings report. This upward adjustment reflects positive performance metrics, although specific earnings figures or percentage increases were not detailed. The revised target suggests analysts have confidence in JNJ's growth trajectory and profitability. As a result, the expectation of improved stock performance could influence investor sentiment and trading activity in JNJ shares.
Read More
Johnson & Johnson (JNJ) Analyst Insights on Potential Price Drops
Limited data available — the article discusses Jim Cramer's perspective on Johnson & Johnson (JNJ), suggesting that if the stock experiences a significant decline, investors should consider buying. However, no specific price targets, trading volumes, or percentage changes are provided. The insights reflect market sentiment but lack concrete data that would impact decision-making or stock evaluation. As such, the article does not offer any verified facts or numbers relevant to JNJ's current financial standing.
Read More
J&J (JNJ) Q1 Revenue Surges 10% to $24.1B, Beats Analyst Estimates
Johnson & Johnson (JNJ) reported first-quarter revenue of $24.1 billion, a nearly 10% increase from the previous year, surpassing analyst estimates of $23.6 billion. Adjusted earnings were $2.70 per share, exceeding the consensus estimate of $2.66. Key drug sales included $4 billion for Darzalex and $1.6 billion for Tremfya, both outperforming projections, while Stelara sales fell 60% to $656 million. JNJ raised its full-year revenue forecast to a midpoint of approximately $100.8 billion, slightly above Wall Street's estimate of $100.6 billion.
Read More
S&P 500 Rallies 3.6% Following U.S.-Iran Ceasefire Announcement
The S&P 500 closed up 3.6% week-to-date, driven by a ceasefire announcement between the U.S. and Iran. The Nasdaq Composite and Dow also rallied 4.7% and 3%, respectively, marking their best week since November. President Trump's announcement of a two-week pause on Iranian strikes has alleviated market tensions. However, financial commentator Jim Cramer expressed concerns about market overconfidence and ongoing geopolitical risks, advising caution ahead of upcoming corporate earnings reports, including Goldman Sachs (GS) and Johnson & Johnson (JNJ).
Read More